Human Factors Engineering for 510(k) Submissions: When HFE Data Is Required and What FDA Expects

Human Factors Engineering for 510(k) Submissions: What FDA Actually Expects

Human factors engineering (HFE) and usability engineering (UE) have shifted from regulatory afterthought to front-and-center submission requirement. If you are preparing a 510(k) and assuming HFE is only relevant for complex devices or high-risk applications, you are likely underestimating what FDA reviewers will ask for -- and potentially setting yourself up for a costly Additional Information (AI) request or an outright Not Substantially Equivalent (NSE) decision.

This post breaks down when HFE data is required, what the agency expects to see, and how to structure your approach so your submission holds up under scrutiny.

The Regulatory Foundation: What Governs HFE in Device Submissions

FDA's expectations for human factors are grounded in several intersecting documents. The primary reference is the 2016 guidance, 'Applying Human Factors and Usability Engineering to Medical Devices,' which replaced the earlier 2011 draft and remains the operative standard. This guidance aligns with the process outlined in IEC 62366-1:2015 (and its 2020 amendment), the international standard for usability engineering that FDA explicitly recognizes.

Additionally, FDA issued a companion guidance in 2016 titled 'Human Factors Studies and Related Clinical Study Considerations in Combination Product Design and Development,' which is relevant if your device incorporates a drug or biologic component. For combination products and delivery devices, this is essential reading.

Under 21 CFR Part 820 -- the Quality System Regulation -- design controls (820.30) require manufacturers to address use-related risks as part of the design and development process. The 2024 transition to 21 CFR Part 820 aligned with ISO 13485:2016 does not eliminate this obligation; it reinforces it. HFE is not a standalone regulatory box to check -- it is embedded in your design history file (DHF) and should be traceable through your entire development process.

When Is HFE Data Required in a 510(k)?

FDA does not require a full summative usability study for every 510(k). However, the threshold for what constitutes 'required' is lower than most startup founders realize. According to FDA's 2016 HFE guidance, a human factors validation study -- also called a summative study -- is expected when:

• The device has a novel user interface not seen in the predicate
• The device is used in a high-risk context where use errors could result in serious harm or death
• The device is intended for lay users or home use, where the use environment is uncontrolled
• The device involves complex multi-step operation or critical tasks that are sensitive to user error
• There are known use-related problems associated with similar device types in FDA's MAUDE database or published literature

Even when a summative study is not required, FDA generally expects at minimum a Human Factors Summary Report that documents your use-related risk analysis (URRA), the critical tasks you identified, any formative studies conducted, and your rationale for concluding that no summative study was necessary. Submitting a 510(k) with no HFE section and no documented rationale is one of the fastest ways to attract an AI request.

What the Human Factors Summary Report Should Cover

When FDA reviewers open your 510(k), they want to see a coherent story -- not a collection of disconnected documents. A well-structured HFE section typically includes:

• Intended users, uses, and use environments: Be specific. 'Healthcare professionals' is not sufficient. Specify training levels, clinical settings, and user populations including those with potential limitations.
• Use-related risk analysis (URRA): Identify all critical tasks, potential use errors, and the severity of harm associated with those errors. This feeds directly into your risk management file per ISO 14971.
• Summary of formative studies: Early-stage cognitive walkthroughs, expert reviews, or prototype testing that shaped your design decisions. FDA wants evidence that HFE was iterative, not cosmetic.
• Summative study protocol and results (if applicable): If a validation study was conducted, document participant selection rationale, simulated use scenarios, critical task pass/fail criteria, and how you resolved any observed use errors.
• Conclusion and residual risk: A clear statement that the device can be used safely and effectively by the intended population under realistic conditions.

Common Mistakes That Delay Clearance

After supporting dozens of 510(k) submissions, the HFE-related deficiencies we see most often are predictable. Device teams conduct summative testing with participants who are too expert relative to the actual user population. Critical tasks are defined too narrowly to avoid failures rather than to reflect realistic use. Instructions for use (IFU) validation is treated as a formality. And perhaps most commonly, HFE documentation is assembled late in the process -- after design freeze -- when iterating in response to observed use errors is no longer practical.

FDA reviewers are trained to look for these gaps. The 2019 'List of Highest Priority Devices for Human Factors Review' signals specific device categories where reviewers will scrutinize HFE submissions most aggressively, including infusion pumps, combination inhalers, home-use diagnostics, and surgical robotics interfaces.

Integrating HFE Into Your 510(k) Strategy Early

The single most effective thing a regulatory team can do is treat HFE as a design input -- not a submission deliverable. That means conducting a URRA before design freeze, using formative study findings to drive design changes, and documenting every decision. When clearance timelines are tight, it is tempting to compress HFE activities. That compression almost always costs more time than it saves when FDA comes back with questions.

If your device is in an FDA-designated priority category or your predicate device has a well-documented adverse event history tied to use error, engage with HFE planning at the program kickoff -- not six months before submission.

Work With a Team That Knows What FDA Expects

At ADB Consulting and CRO Inc., we help medical device companies build HFE programs that are defensible, efficient, and aligned with current FDA expectations. Whether you need a gap assessment on your existing usability documentation, help structuring your URRA, or end-to-end support for a summative validation study, we bring the regulatory expertise to get it right the first time.

Do not let HFE become the reason your 510(k) stalls. Book a free discovery call with Andre Butler and the ADB team today at adbccro.com to discuss your device, your timeline, and a clear path to clearance.